Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 6Neoplasms 5Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Vomiting 1Stomatitis 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Alveolar Soft Part 1Renal Insufficiency 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Paraproteinemias 1Oncology Patients Receiving Chemotherapy 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Nausea 1NSCLC 1Mucositis 1Mastocytosis, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1

Interventions

blinatumomab 9Cyclophosphamide 7Rituximab 6Lenalidomide 6Dexamethasone 5Azacitidine 5venetoclax 4fludarabine 4Cytarabine 4fludarabine phosphate 3Maintenance 3Busulfan 3tislelizumab 2thymoglobulin 2pembrolizumab 2obinutuzumab 2daratumumab 2Whole-Body Irradiation 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Methotrexate 2Melphalan 2Immunotherapy 2Imatinib Mesylate 2Drug Therapy 2Docetaxel 2Decitabine 2Clofarabine 2Cladribine 2Carboplatin 2Calcium Dobesilate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasm, Residual × Diphenhydramine × Clear all
NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
69 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡